NSE · FERMENTA · Pharmaceuticals
Fermenta Biotech Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹110 Cr with net profit ₹22 Cr — a 19.63% net margin, versus 13.1% the period before.
Shareholding
As of 2026-06-30
- Promoter64.09%
- Public35.75%
- FII0.13%
- DII0.04%
14,131 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.93× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #10 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,09,787 Cr | 279.14 | 12.49 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹26,002 Cr | 197.39 | 15.73 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,621 Cr | 68.18 | 13.14 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,402 Cr | 128.08 | 2.15 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,791 Cr | 68.66 | 2.45 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,572 Cr | 35.02 | 4.55 | 12.98% | 11.5% |
| Hikal Limited | ₹2,689 Cr | 186.41 | 2.25 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,248 Cr | 248.38 | 9.19 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,017 Cr | 41.93 | 6.13 | 14.62% | 9.59% |
| Fermenta Biotech Ltd.(this company) | ₹1,351 Cr | 68.92 | 3.24 | 17.67% | 13.66% |
AI analysis
AI-generated · google/gemini-2.5-flashFermenta Biotech Ltd. (symbol 506414) operates in the Pharmaceuticals sector. The company has a market capitalization of Rs 1282 Cr, with a PE ratio of 19.22 and an EPS of 22.67. The book value stands at Rs 138.15. Return on equity (ROE) is 17.67% and return on capital employed (ROCE) is 20.02%. The debt-to-equity ratio is 0.39, while the profit margin is 13.66%. The 52-week high for the share price was Rs 479.45 and the 52-week low was Rs 248.85.
Positives
- +The company has a low debt-to-equity ratio of 0.39.
- +Promoter shareholding is substantial at 64.09% as of Mar 2026.
- +No promoter shares are pledged, with a promoter pledge of 0% as of Mar 2026.
Negatives
- −Profit margin for the most recent quarter (Mar 2026) is 15.78% (19.19 Cr net profit / 121.58 Cr revenue), which is lower than the full-year profit margin of 13.66%.
- −Net profit saw a decline in the last two reported quarters, from Rs 18.06 Cr in Sept 2025 to Rs 12.68 Cr in Dec 2025, and then increased to Rs 19.19 Cr in Mar 2026, but is still lower than the prior peak.
- −The dividend yield is 84%, which could indicate a large one-time dividend rather than a sustainable high yield, or a miscited figure from the source data.
- −The stock is currently under ST-ASM · ASM 1 surveillance measures.
Financial performance
In the annual period ending Mar 2025, Fermenta Biotech Ltd. reported a revenue of Rs 481.30 Cr and a net profit of Rs 76.86 Cr, with an EPS of 26.35. For the most recent quarterly period ending Mar 2026, revenue was Rs 121.58 Cr and net profit was Rs 19.19 Cr. This follows a net profit of Rs 12.68 Cr on a revenue of Rs 137.36 Cr in Dec 2025.
Profitability & returns
The company maintained a profit margin of 13.66%. Return on equity (ROE) was 17.67%, and return on capital employed (ROCE) was 20.02%. The annual net profit for Mar 2025 was Rs 76.86 Cr, with EPS at 26.35 for the same period.
Balance sheet
Fermenta Biotech Ltd. has a debt-to-equity ratio of 0.39. The book value per share is Rs 138.15. The annual EBIDTA for Mar 2025 was Rs 97.40 Cr. No further details on the balance sheet were provided.
Ownership & pledges
As of Mar 2026, promoters held 64.09% of the shares, with no promoter shares pledged. Public shareholding was 35.89%. FIIs held 0.02% and DIIs held 0.00% of the shares. The total number of shareholders was 13,661.
Regulatory & surveillance
Fermenta Biotech Ltd. is listed under the ST-ASM · ASM 1 surveillance framework, indicating specific monitoring measures are in place due to short-term additional surveillance measures.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.